Efficacy and tolerability of almotriptan in postmarketing surveillance studies

European Neurology

Volumn 53, Issue 1 SUPPL., 2005, Pages 34-40

  Pascual, Julio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

2 hour pain free; Early intervention; Migraine; Neurologist; Postmarketing surveillance study; Primary care; Randomized controlled trial; Sustained pain free; Triptan

Indexed keywords

ACETYLSALICYLIC ACID PLUS METOCLOPRAMIDE; ALMOTRIPTAN; ANTIMIGRAINE AGENT; CAFERGOT; DICLOFENAC POTASSIUM; ELETRIPTAN; ISOMETHEPTENE MUCATE PLUS DICHLORALPHENAZONE PLUS ACETAMINOPHEN; KETOPROFEN; LYSINE ACETYLSALICYLATE PLUS METOCLOPROMIDE; PLACEBO; SUMATRIPTAN; TOLFENAMIC ACID; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ABDOMINAL PAIN; ANALGESIA; BIOASSAY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLOW UP; GENERAL PRACTICE; GERMANY; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; NAUSEA; OUTCOMES RESEARCH; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIAN; POPULATION RESEARCH; POPULATION SIZE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SPAIN; STANDARD; THORAX DISEASE; TIME;

GERMANY; HUMANS; INDOLES; MIGRAINE DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SPAIN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 20444443093     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085040     Document Type: Conference Paper

References (22)

1. Breslau N, Rasmussen BK: The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology 2001;56:S4-S12.
2. Lipton RB, Stewart WF: Migraine headaches: Epidemiology and comorbidity. Clin Neurosci 1998;5:2-9.
3. Breslau N, Merikangas K, Bowden CL: Comorbidity of migraine and major affective disorders. Neurology 1994;44:S17-S22.
4. Joish VV, Cady P, Bennett D, Harris R: An epidemiological case-control study of migraine and its associated comorbid conditions. Ann Epidemiol 2000;10:460.
5. Shechter AL, Lipton RB, Silberstein SD. Migraine comorbidity; in: Silberstein SD, Lipton RD, Dalessio DJ (eds): Wolff's Headache and Other Headache Pain. New York, Oxford University Press, 2001, pp 108-118.
6. Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-1287.
7. Dodick DW, Martin VT, Smith T, Silberstein S: Cardiovascular tolerability and safety of triptans: A review of clinical data. Headache 2004;44(Suppl 1):S20-30.
8. Dodick D, Martin V: Triptans and CNS side-effects: Pharmacokinetic and metabolic mechanisms. Cephalalgia 2004;24:417-424.
9. Levels of evidence in AFP. American Academy of Family Physicians. Available at: http://www.aafp.org/x17444.xml. Accessed September 26, 2004.
10. Lipton RB: Studying the migraine studies: Methodological issues in comparative trials of acute medications. Am J Clin Proc 2001;1:51-57.
11. Tfelt-Hansen P, Goldstein J, Malbecq W, Lines C: Comparison of rizatriptan and sumatriptan: A reply to O'Quinn et al. Headache 1999;39:340-341.
12. Lipton RB, Stewart WF, Stone AM, Lainez MJ, Sawyer JP: Stratified care vs step care strategies for migraine: The disability in strategies of care (DISC) study: A randomized trial. JAMA 2000;284:2599-2605.
13. Lipton RB, Bigal ME, Goadsby PJ: Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia 2004;24:321-332.
14. Edmeads J: Defining response in migraine: which endpoints are important? Eur Neurol 2005;53(suppl 1):22-28.
15. Ferrari MD: Should we advise patients to treat migraine attacks early: methodological issues. Eur Neurol 2005;53(suppl 1):17-21.
16. Mathew NT: Efficacy and tolerability of almotriptan in controlled clinical trials. Eur Neurol 2005;53(suppl 1):29-33.
17. Pascual J, Cabarrocas X: Within-patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache 2002;42:28-31.
18. Mathew NT: Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003;43:1075-1079.
19. Pascual J, Lainez JM, Leira R, Titus F, Mateos V, Galvan J: [almotriptan in the treatment of migraine attacks in clinical practice: Results of the TEA 2000 observational study]. Neurologia 2003;18:7-17.
20. Pascual J, Tranche S, Leira R, Lainez JM, Mateos V, Galvan J: Almotriptan in clinical practice: Experience in primary care vs. neurology setting. Headache 2003;43:525.
21. Diener HC: Consistency of almotriptan 12.5 mg tablets across multiple migraine attacks when used in routine clinical settings in Germany. Headache 2004;44:471.
22. Diener HC: Satisfaction with almotriptan 12.5 mg for treating multiple migraine attacks: An observational study in routine clinical settings in Germany. Headache 2004;44:470-471.